A5036907494- Receptor Mechanisms and Signaling
- Monoclonal and Polyclonal Antibodies Research
- Protein Kinase Regulation and GTPase Signaling
- Computational Drug Discovery Methods
- Advanced Proteomics Techniques and Applications
- Cancer therapeutics and mechanisms
- Cell Image Analysis Techniques
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- RNA and protein synthesis mechanisms
- Cancer, Hypoxia, and Metabolism
- Medical Imaging Techniques and Applications
- 3D Printing in Biomedical Research
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Nanoparticle-Based Drug Delivery
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Nanoplatforms for cancer theranostics
- Protease and Inhibitor Mechanisms
- RNA Interference and Gene Delivery
- bioluminescence and chemiluminescence research
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
Pfizer (United States)
2021-2025
Global Science & Technology (United States)
2021
Ansys (United States)
2002
Abstract A dysregulated cell cycle is a hallmark of cancer and inhibition cyclin dependent kinases (CDKs) proven therapeutic strategy in treating HR+/HER2- breast variety other cancers. 18F-FLT (18F-3'-deoxy-3'-fluorothymidine) validated positron emission tomography (PET) biomarker to measure proliferation. Here we show the utility PET imaging as pharmcodynamic (PD) differentiating efficacy PF-07104091 (CDK2 selective inhibitor) Palbociclib (CDK4/6 sensitive resistant tumor models. was...
Unlike the majority of cancers, survival for lung cancer has not shown much improvement since early 1970s and rates remain low. Genetically engineered mice tumor models are high translational relevance as we can generate tissue specific mutations which observed in patients. Since these tumors cannot be detected quantified by traditional methods, use micro-computed tomography imaging longitudinal evaluation to measure response therapy. Conventionally, analyze microCT images via a manual...
IL13Rα2 is a cell surface tumor antigen that overexpressed in multiple types. Here, we studied biodistribution and targeting potential of an anti-IL13Rα2 antibody (Ab) anti-tumor activity anti-IL13Rα2-antibody-drug conjugate (ADC). The Ab was labeled with fluorophore AF680 or radioisotope 89Zr for vivo tracking using fluorescence molecular tomography (FMT) positron emission (PET) imaging, respectively. Both imaging modalities showed the major uptake site anti-IL13Rα2-Ab, peak 5–8% ID 10%...
Lung cancer remains a leading cause of cancer-related death, but scientists have made great strides in developing new treatments recently, partly owing to the use genetically engineered mouse models (GEMMs). GEMM tumors represent translational model that recapitulates human disease better than implanted because develop spontaneously lungs. However, detection these relies on vivo imaging tools, specifically micro-Computed Tomography (micro-CT or µCT), and image analysis can be laborious with...
<p>Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A, sotorasib</p>
<p>Structure of Compound A</p>
<p>Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment the PET imaging cohort animals</p>
<p>G12C KP model survival data from long-term treatment with Compound A</p>
<p>Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models</p>
<div>Abstract<p>KRAS is one of the most commonly mutated oncogenes in lung, colorectal, and pancreatic cancers. Recent clinical trials directly targeting KRAS G12C presented encouraging results for a large population non-small cell lung cancer (NSCLC), but resistance to treatment concern. Continued exploration new inhibitors preclinical models needed address mechanisms improve duration patient responses. To further enable development inhibitors, we present framework involving...
<p>Individual MLAST curves and biomarker staining from G12C KP animals treated with vehicle, Compound A, sotorasib</p>
<p>Baseline and post-treatment PET/CT images of individual KrasLSL-G12C/wtp53fl/fl animals treated with vehicle or Compound A</p>
<p>Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models</p>
<p>Supplementary Methods Section</p>
<p>Compound A modulates glucose metabolism and pERK signaling in MiaPaCa2 tumors after 3 days of treatment the PET imaging cohort animals</p>
<p>G12C KP model survival data from long-term treatment with Compound A</p>
<p>Tolerability and individual MiaPaCa2 tumor growth data from animals treated with two weeks of Compound A</p>
<p>Structure of Compound A</p>
<p>Tolerability and individual MiaPaCa2 tumor growth data from animals treated with two weeks of Compound A</p>